Val-pro containing .alpha.-keto oxadiazoles as serine protease inhibitors
US6001813A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Jun 3, 1998 |
| Grant date | Dec 14, 1999 |
| Priority date | — |
| Expiry date | Jun 3, 2018 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to certain substituted oxadiazole tripeptides, which are useful as inhibitors of human neutrophil elastase (HNE) for the treatment of HNE-mediated processes implicated in conditions such as adult respiratory distress syndrome, septic shock and multiple organ failure. A series of studies also have indicated the involvement HNE in myocardial ischemia-reperfusion injury, emphysema. HNE-mediated processes are implicated in other conditions such as arthritis, periodontal disease, glomerulonephritis, dermatitis, psoriasis, cystic fibrosis, chronic bronchitis, atherosclerosis, Alzheimer's disease, organ transplantation, corneal ulcers, and invasion behavior of malignant tumors.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.